| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: EMD Serono |
| Recipient: You |
| Company: BioNTech |
| Recipient: You |
| Company: Shattuck |
| Recipient: You |
| Company: Bayer |
| Recipient: You |
| Company: Debiopharm Group |
| Recipient: You |
| Company: Ipsen |
| Recipient: You |
| Company: Gilead Sciences |
| Recipient: You |
| Company: Bicara Therapeutics |
| Recipient: You |
| Company: BioNTech AG |
| Recipient: You |
| Company: Nektar |
| Recipient: You |
| Company: Istari |
| Recipient: You |
| Company: LLX Solutions |
| Recipient: You |
| Company: OncLive |
| Recipient: You |
| Company: Seagen |
| Recipient: You |
| Company: Kura |
| Recipient: You |
| Company: Mirati |
| Recipient: You |
| Company: Eisai |
| Recipient: You |
| Company: Exelixis |
| Recipient: You |
| Company: ITeos Therapeutics |
| Recipient: You |
| Company: Caladrius Biosciences |
| Recipient: You |
| Company: Coherus Biosciences |
| Recipient: You |
| Company: Surface |
| Recipient: You |
| Company: Merus |
| Recipient: You |
| Company: Adaptimmune |
| Recipient: You |
| Company: END Merck |
| Recipient: You |
| Company: Bristol-Myers Squibb/Roche |
| Recipient: You |
| Company: BioNTech SE |
| Recipient: You |
| Company: Journal of Clinical Oncology |
| Recipient: You |
| Company: Axiom Biotechnologies |
| Recipient: You |
| Company: Aptitude Health |
| Recipient: You |
| Company: EMD Serono |
| Recipient: You |
| Company: Bicara Therapeutics |
| Recipient: You |
| Company: Guidepoint Global |
| Recipient: You |
| Company: Coherus Biosciences |
| Recipient: You |
| Company: LLX Solutions |
| Recipient: You |
| Company: Abbvie |
| Recipient: You |
| Company: Pfizer |
| Recipient: You |
| Company: Brightly Network |
| Recipient: You |
| Company: Boxer Capital |
| Recipient: You |
| Company: Merus |
| Recipient: You |
| Company: EMD Serono |
| Recipient: You |
| Company: Takeda |
| Recipient: You |
| Company: Suzhou Liangyihui Network Technology |
| Recipient: You |
| Company: Sensei Biotherapeutics |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Genocea Biosciences |
| Recipient: Your Institution |
| Company: Cullinan |
| Recipient: Your Institution |
| Company: Genentech |
| Recipient: Your Institution |
| Company: Agenus |
| Recipient: Your Institution |
| Company: Kura |
| Recipient: Your Institution |
| Company: Seagen |
| Recipient: Your Institution |
| Company: Abbvie |
| Recipient: Your Institution |
| Company: BioNTech SE |
| Recipient: Your Institution |
| Company: NRG Oncology |
| Recipient: Your Institution |
| Company: INVAX |
| Recipient: Your Institution |
| Company: Merus |
| Recipient: Your Institution |
| Company: Gilead Sciences |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Roche |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: PCT/US2022/023911
pending
Board of Regents, The University of Texas System
|
| Recipient: You |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| No Relationships to Disclose |
|
|